Lipid nanoparticles for brain targeting III. Long-term stability and in vivo toxicity

International Journal of Pharmaceutics

Volumn 454, Issue 1, 2013, Pages 316-323

  Blasi, Paolo ^a   Schoubben, Aurélie ^a   Traina, Giovanna ^a   Manfroni, Giuseppe ^a   Barberini, Lanfranco ^a   Alberti, Paolo Francesco ^a   Cirotto, Carlo ^a   Ricci, Maurizio ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Acute toxicity; Chorioallantoic membrane (CAM) assay; Long term stability; Nanoparticles (NPs); Solid lipid nanoparticles (SLN)

Indexed keywords

POLYETHYLENE; SOLID LIPID NANOPARTICLE;

ACUTE TOXICITY; ANIMAL EMBRYO; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; BRAIN TOXICITY; CHORIOALLANTOIS; CONTROLLED STUDY; DEGRADATION; DRUG DELIVERY SYSTEM; DRUG STABILITY; EMBRYO; HISTOLOGY; HUMIDITY; HYDRODYNAMICS; IN VIVO STUDY; LONG TERM EXPOSURE; NANOENCAPSULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; ROOM TEMPERATURE; SHEAR STRESS; STORAGE; SURFACE CHARGE; TARGET ORGAN;

EID: 84884126183     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.06.037     Document Type: Article

References (39)

1. Ballabh, P., Braun, A., Nedergaard, M., 2004. The blood-brain barrier: an overview structure, regulation, and clinical implications. Neurobiol. Dis. 16, 1-13. (Pubitemid 38569790)
2. Beccari, N., Mazzi, V., 1966. Manuale di tecnica microscopica. Guida pratica alla ricerca istologica e istochimica. Società Editrice Libraria, Milan.
3. Blasi, P., Giovagnoli, S., Schoubben, A., Ricci, M., Rossi, C., 2007. Solid lipid nanoparticles for targeted brain drug delivery. Adv. Drug Deliv. Rev. 59, 454-477. (Pubitemid 47259226)
4. Blasi, P., Schoubben, A., Giovagnoli, S., Puglia, C., Barberini, L., Cirotto, C., Rossi, C., Ricci, M., 2009. Colloidal dispersions for targeted brain drug delivery. Eur. J. Pharm. Sci. 38S, 25-26.
5. Blasi, P., Schoubben, A., Giovagnoli, S., Rossi, C., Ricci, M., 2011a. Solid lipid nanoparticles to improve brain drug delivery. In: Kumar, C. (Ed.), Nanomaterials for the Life Sciences. Wiley-VCH, Weinheim, pp. 365-394.
6. Blasi, P., Giovagnoli, S., Schoubben, A., Puglia, C., Bonina, F., Rossi, C., Ricci, M., 2011b. Lipid nanoparticles for brain targeting I. Formulation optimization. Int. J. Pharm. 419, 287-295.
7. Blasi, P., Mouldon, L., Barberini, L., Cirotto, C., Ricci, M., Neuwelt, E.A., 2011c. In vitro and in vivo characterization of lipid nanoparticles for brain drug targeting. In: CRS Italy Chapter Workshop.
8. Blasi, P., Caliceti, P., De Rosa, G., Haas, H., Maio, M., Matricardi, P., Salmaso, S., 2012. Outcomes from the CRS Italy local chapter workshop roundtable: translation of controlled release platforms from bench to bedside up to marketed products. CRS Newslett. 29, 20-21.
9. Budai, P., Várnagy, L., Fejes, S., Somlyay, I.M., Linczmayer, K., Pongrácz, A., 2004. Irritative effects of some pesticides and a technical component on tissue structure of the chorioallantoic membrane. Commun. Agric. Appl. Biol. Sci. 69, 807-809.
10. Fredrick, E., 2010. Factors governing partial coalescence in oil-in-water emulsions. Adv. Colloid Interface Sci. 2153, 30-42.
11. Gao, K., Jiang, X., 2006. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int. J. Pharm. 310, 213-219. (Pubitemid 43287986)
12. Gonzalez-Mira, E., Egea, M.A., Garcia, M.L., Souto, E.B., 2010. Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Colloids Surf. B: Biointerfaces 81, 412-421.
13. Göppert, T.M., Müller, R.H., 2005. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J. Drug Target. 13, 179-187. (Pubitemid 40668171)
14. Han, C., Qi, C.M., Zhao, B.K., Cao, J., Xie, S.Y., Wang, S.L., Zhou, W.Z., 2009. Hydrogenated castor oil nanoparticles as carriers for the subcutaneous administration of tilmicosin: in vitro and in vivo studies. J. Vet. Pharmacol. Ther. 32, 116-123.
15. Hippalgaonkar, K., Majumdar, S., Kansara, V., 2010. Injectable lipid emulsions - advancements, opportunities and challenges. AAPS PharmSciTech 11, 1526-1540.
16. Immordino, M.L., Dosio, F., Cattel, L., 2006. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed. 1, 297-315.
17. Kaur, I.P., Bhandari, R., Bhandari, S., Kakkar, V., 2008. Potential of solid lipid nanoparticles in brain targeting. J. Control. Release 127, 97-109.
18. Lawrence, R.S., Groom, M.H., Ackroyd, D.M., Parish, W.E., 1986. The chorioallantoic membrane in irritation testing. Food Chem. Toxicol. 24, 497-502. (Pubitemid 17183986)
19. Monopoli, M.P., Walczyk, D., Campbell, A., Elia, G., Lynch, I., Baldelli Bombelli, F., Dawson, K.A., 2011. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J. Am. Chem. Soc. 133, 2525-2534.
20. Müller, R.H., Radtke, M., Wissing, S.A., 2004. Solid lipid nanoparticles and nanostructured lipid carriers. In: Nalwa, H.S. (Ed.), Encyclopedia of Nanoscience and Nanotechnology. American Scientific Publishers, Los Angeles, pp. 43-56.
21. Müller, R.H., Rühl, D., Runge, S., Schulze-Forster, K., Mehnert, W., 1997. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res. 14, 458-462. (Pubitemid 27205004)
22. Neuwelt, E.A., 2004. Mechanisms of disease: the blood-brain barrier. Neurosurgery 54, 131-140.
23. Neuwelt, E.A., Bauer, B., Fahlke, C., Fricker, G., Iadecola, C., Janigro, D., Leybaert, L., Molnár, Z., O'Donnell, M.E., Povlishock, J.T., Saunders, N.R., Sharp, F., Stanimirovic, D., Watts, R.J., Drewes, L.R., 2011. Engaging neuroscience to advance translational research in brain barrier biology. Nat. Rev. Neurosci. 12, 169-182.
24. Paolino, D., Cosco, D., Molinaro, R., Celia, C., Fresta, M., 2011. Supramolecular devices to improve the treatment of brain diseases. Drug Discovery Today 16, 311-324.
25. Pardridge, W.M., 2011. Brain Drug Targeting: The Future of Brain Drug Development. Cambridge University Press, Cambridge.
26. Saw, C.L.L., Heng, P.W.S., Liew, C.V., 2008. Chick chorioallantoic membrane as an in situ biological membrane for pharmaceutical formulation development: a review. Drug Dev. Ind. Pharm. 34, 1168-1177.
27. Schoubben, A., Blasi, P., Marenzoni, M.L., Barberini, L., Giovagnoli, S., Cirotto, C., Ricci, M., 2013. Capreomycin supergenerics for pulmonary tuberculosis treatment: preparation, in vitro, and in vivo characterization. Eur. J. Pharm. Biopharm. 83, 388-395.
28. Shawahna, R., Uchida, Y., Declèves, X., Ohtsuki, S., Yousif, S., Dauchy, S., Jacob, A., Chassoux, F., Daumas-Duport, C., Couraud, P.O., Terasak, T., Scherrmann, J.M., 2011. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol. Pharmacol. 8, 1332-1341.
29. Shegokar, R., Singh, K.K., Müller, R.H., 2011. Production and stability of stavudine solid lipid nanoparticles - from lab to industrial scale. Int. J. Pharm. 416, 461-470.
30. Silva, A.C., Kumar, A., Wild, W., Ferreira, D., Santos, D., Forbes, B., 2012. Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles. Int. J. Pharm. 436, 798-805.
31. Souto, E.B., Martins-Lopes, P., Lopes, C.M., Gaivão, I., Silva, A.M., Guedes-Pinto, H., 2009. A note on regulatory concerns and toxicity assessment in lipid-based delivery systems (LDS). J. Biomed. Nanotechnol. 5, 317-322.
32. Tosi, G., Bondioli, L., Ruozi, B., Badiali, L., Severini, G.M., Biffi, S., De Vita, A., Bortot, B., Dolcetta, D., Forni, F., Vandelli, M.A., 2011. NIR-labeled nanoparticles engineered for brain targeting: in vivo optical imaging application and fluorescent microscopy evidences. J. Neural Transm. 118, 145-153.
33. Valdes, T.I., Kreutzer, D., Moussy, F., 2002. The chick chorioallantoic membrane as a novel in vivo model for the testing of biomaterials. J. Biomed. Mater. Res. 62, 273-282. (Pubitemid 34988505)
34. Vargas, A., Zeisser-Labouèbe, M., Lange, N., Gurny, R., Delie, F., 2007. The chick embryo and its chorioallantoic membrane (CAM) for the in vivo evaluation of drug delivery systems. Adv. Drug Deliv. Rev 59, 1162-1176. (Pubitemid 47615205)
35. Wagner, W., Dullaart, A., Bock, A.-K., Zweck, A., 2006. The emerging nanomedicine landscape. Nat. Biotechnol. 24, 1211-1217. (Pubitemid 44564760)
36. Weyhers, H., Ehlers, S., Hahn, H., 2006a. Solid lipid nanoparticles (SLN) - effects of lipid composition on in vitro degradation and in vivo toxicity. Pharmazie 61, 539-544. (Pubitemid 43989132)
37. Weyhers, H., Löbenberg, R., Mehnert, W., Souto, E.B., Kreuter, J., Müller, R.H., 2006b. In vivo distribution of 125I-radiolabelled solid lipid nanoparticles. Pharm. Ind. 68, 889-894. (Pubitemid 44517606)
38. Wissing, S.A., Kayser, O., Müller, R.H., 2004. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 56, 1257-1272. (Pubitemid 38510473)
39. Zensi, A., Begley, D., Pontikis, C., Legros, C., Mihoreanu, L., Wagner, S., Büchel, C., von Briesen, H., Kreuter, J., 2009. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J. Control. Release 137, 78-86.